Business Context and Reporting Period
This Form 8-K is filed by Renovaro, Inc. (not Lunai Bioworks Inc.) on March 6, 2025, reporting events occurring on February 28, 2025. The filing details an amendment to a binding Letter of Intent (LOI) entered into on January 1, 2025, regarding the proposed acquisition of Predictive Oncology Inc. by Renovaro.
Key Financial Metrics and Transaction Details
The filing does not provide Renovaro's standalone revenue, profit, cash flow, or debt metrics. Financial data is limited to the specific terms of the transaction amendment:
- Immediate Acquisition: Renovaro acquired 467,290 shares of Predictive Oncology common stock for an aggregate purchase price of $500,000.
- Contingent Purchase: Renovaro agreed to purchase an additional 901,298 shares of Predictive Oncology common stock for an aggregate of $964,389, subject to the execution of a definitive agreement.
- Total Committed Capital (Transaction Specific): $1,464,389 (subject to definitive agreement execution for the second tranche).
Material Changes Versus Prior Period
On February 28, 2025, Renovaro and Predictive Oncology executed an Extension Agreement amending the original LOI. Key changes include:
- Termination Date Extension: The outside termination date of the LOI was extended from February 28, 2025, to March 31, 2025.
- Scope Adjustment: The agreement eliminated Renovaro's obligation to acquire certain shares of Predictive Oncology's common stock that were previously outlined in the LOI.
Guidance, Outlook, Risks, and Contingencies
Outlook and Next Steps: The parties intend to file a Registration Statement on Form S-4, which will include a preliminary proxy statement and prospectus. The transaction is contingent upon the execution of a definitive agreement and approval by Predictive Oncology stockholders.
Risks and Contingencies: The filing highlights significant risks, including:
- Failure of Predictive Oncology stockholders to approve the transaction.
- Failure to obtain necessary regulatory or licensure approvals.
- Adverse effects on Renovaro's stock price or business relationships.
- Inability to retain key personnel.
- General economic and industry-specific conditions.
Forward-Looking Statements: The document contains forward-looking statements regarding future financial position and results of operations, which are subject to uncertainties and may differ materially from actual results.
Important Facts for Investor Verification
- Verify the identity of the registrant as Renovaro, Inc. (Ticker: RENB), noting the discrepancy with the requested company name "Lunai Bioworks Inc."
- Confirm the status of the definitive agreement required to trigger the $964,389 contingent purchase of additional shares.
- Monitor the upcoming filing of the Form S-4 Registration Statement for complete transaction terms and proxy details.
- Review the March 31, 2025, deadline for the LOI termination date to assess the likelihood of deal completion.
- Check for any subsequent filings regarding stockholder approval of the proposed acquisition.